Literature DB >> 26017344

Accuracy of dose planning for prostate radiotherapy in the presence of metallic implants evaluated by electron spin resonance dosimetry.

G G Alves1, A Kinoshita1, H F de Oliveira2, F S Guimarães2, L L Amaral2, O Baffa1.   

Abstract

Radiotherapy is one of the main approaches to cure prostate cancer, and its success depends on the accuracy of dose planning. A complicating factor is the presence of a metallic prosthesis in the femur and pelvis, which is becoming more common in elderly populations. The goal of this work was to perform dose measurements to check the accuracy of radiotherapy treatment planning under these complicated conditions. To accomplish this, a scale phantom of an adult pelvic region was used with alanine dosimeters inserted in the prostate region. This phantom was irradiated according to the planned treatment under the following three conditions: with two metallic prostheses in the region of the femur head, with only one prosthesis, and without any prostheses. The combined relative standard uncertainty of dose measurement by electron spin resonance (ESR)/alanine was 5.05%, whereas the combined relative standard uncertainty of the applied dose was 3.35%, resulting in a combined relative standard uncertainty of the whole process of 6.06%. The ESR dosimetry indicated that there was no difference (P>0.05, ANOVA) in dosage between the planned dose and treatments. The results are in the range of the planned dose, within the combined relative uncertainty, demonstrating that the treatment-planning system compensates for the effects caused by the presence of femur and hip metal prostheses.

Entities:  

Mesh:

Year:  2015        PMID: 26017344      PMCID: PMC4512104          DOI: 10.1590/1414-431X20154367

Source DB:  PubMed          Journal:  Braz J Med Biol Res        ISSN: 0100-879X            Impact factor:   2.590


  16 in total

1.  Tissue heterogeneity in IMRT dose calculation for lung cancer.

Authors:  Katia Pasciuti; Giuseppe Iaccarino; Lidia Strigari; Tiziana Malatesta; Marcello Benassi; Anna Maria Di Nallo; Alessandra Mirri; Valentina Pinzi; Valeria Landoni
Journal:  Med Dosim       Date:  2010-10-23       Impact factor: 1.482

2.  Use of advanced treatment technologies among men at low risk of dying from prostate cancer.

Authors:  Bruce L Jacobs; Yun Zhang; Florian R Schroeck; Ted A Skolarus; John T Wei; James E Montie; Scott M Gilbert; Seth A Strope; Rodney L Dunn; David C Miller; Brent K Hollenbeck
Journal:  JAMA       Date:  2013-06-26       Impact factor: 56.272

Review 3.  Clinical applications of alanine/electron spin resonance dosimetry.

Authors:  Oswaldo Baffa; Angela Kinoshita
Journal:  Radiat Environ Biophys       Date:  2014-01-08       Impact factor: 1.925

4.  Cancer statistics, 2014.

Authors:  Rebecca Siegel; Jiemin Ma; Zhaohui Zou; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2014-01-07       Impact factor: 508.702

5.  Comparison of late gastrointestinal and genitourinary toxicity of prostate cancer patients undergoing intensity-modulated versus conventional radiotherapy using localized fields.

Authors:  A B Jani; A Su; D Correa; J Gratzle
Journal:  Prostate Cancer Prostatic Dis       Date:  2006-09-19       Impact factor: 5.554

6.  Dose uncertainty in radiotherapy of patients with head and neck cancer measured by in vivo ESR/alanine dosimetry using a mouthpiece.

Authors:  Daniela Wagner; Mathias Anton; Hilke Vorwerk
Journal:  Phys Med Biol       Date:  2011-02-04       Impact factor: 3.609

Review 7.  Quality of life study in prostate cancer patients treated with three-dimensional conformal radiation therapy: comparing late bowel and bladder quality of life symptoms to that of the normal population.

Authors:  A L Hanlon; D Watkins Bruner; R Peter; G E Hanks
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-01-01       Impact factor: 7.038

8.  Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study.

Authors:  Jeff M Michalski; Kyounghwa Bae; Mack Roach; Arnold M Markoe; Howard M Sandler; Janice Ryu; Matthew B Parliament; William Straube; Richard K Valicenti; James D Cox
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-01-01       Impact factor: 7.038

9.  Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.

Authors:  Michael J Zelefsky; Emily J Levin; Margie Hunt; Yoshiya Yamada; Alison M Shippy; Andrew Jackson; Howard I Amols
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-03-15       Impact factor: 7.038

10.  Comparative effectiveness of external-beam radiation approaches for prostate cancer.

Authors:  Bruce L Jacobs; Yun Zhang; Ted A Skolarus; John T Wei; James E Montie; David C Miller; Brent K Hollenbeck
Journal:  Eur Urol       Date:  2012-07-06       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.